TrialArchives of gynecology and obstetrics2026

Safety of a cytomegalovirus-specific hyperimmunoglobulin in the prevention of maternal-fetal transmission after primary infection-results of an open-label, single-arm, prospective trial.

Karl Oliver Kagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.